What's new

PSUSA/00002943/202406

PSUSA/00002943/202406

Mar 3, 2025 - 17:53
 0
PSUSA/00002943/202406
PSUSA/00002943/202406
Read More

Tags:

Previous Article

AbbVie gets into obesity with $350M deal for once-weekly shot

Next Article

Printemps to open New York concept store at One Wall Street

Related Posts

Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system, Online, European Medicines Agency, Amsterdam, the Netherlands, from 12 May 2025 to 16 May 2025

Mandatory use of ISO/ICH E2B(R3) individual case safety...

Feb 14, 2025  0

Human medicines European public assessment report (EPAR): Ituxredi, rituximab, Date of authorisation: 19/09/2024, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 10, 2025  0

Human medicines European public assessment report (EPAR): Karvea, irbesartan, Date of authorisation: 26/08/1997, Revision: 48, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 14, 2025  0